AKT/GSK3 β Signaling in Glioblastoma.

AKT/GSK3β Signaling in Glioblastoma. Neurochem Res. 2016 Aug 27; Authors: Majewska E, Szeliga M Abstract Glioblastoma (GBM) is the most aggressive of primary brain tumors. Despite the progress in understanding the biology of the pathogenesis of glioma made during the past decade, the clinical outcome of patients with GBM remains still poor. Deregulation of many signaling pathways involved in growth, survival, migration and resistance to treatment has been implicated in pathogenesis of GBM. One of these pathways is phosphatidylinositol-3 kinases (PI3K)/protein kinase B (AKT)/rapamycin-sensitive mTOR-complex (mTOR) pathway, intensively studied and widely described so far. Much less attention has been paid to the role of glycogen synthase kinase 3 β (GSK3β), a target of AKT. In this review we focus on the function of AKT/GSK3β signaling in GBM. PMID: 27568206 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27568206?dopt=Abstract

Source: Neurochemical Research - August 26, 2016 Category: Neuroscience Authors: Majewska E, Szeliga M Tags: Neurochem Res Source Type: research